MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Spherix Global Insights

< Previous 1 2 3 4 Next >
Physicians Signal Cautious Enthusiasm for Gene Therapy Across Hematology, But Adoption Remains Selective
From Spherix Global Insights
Via GlobeNewswire
As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Highlights Patient Influence in Shaping PNH Treatment Choices
From Spherix Global Insights
Via GlobeNewswire
AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
From Spherix Global Insights
Via GlobeNewswire
Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology’s Future, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds
From Spherix Global Insights
Via GlobeNewswire
US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas
From Spherix Global Insights
Via GlobeNewswire
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
From Spherix Global Insights
Via GlobeNewswire
Rheumatologists Eagerly Anticipate Pipeline Advancements in Idiopathic Inflammatory Myopathies to Address Deep Unmet Need, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Johnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi
From Spherix Global Insights
Via GlobeNewswire
Beyond Gene Therapy: Pyruvate Kinase Activators (Agios, Novo Nordisk) Offer a New Route to Address Hemoglobin, VOCs, and Transfusion Burden in Sickle Cell Disease
From Spherix Global Insights
Via GlobeNewswire
Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
From Spherix Global Insights
Via GlobeNewswire
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Pulmonologists and Rheumatologists Struggle to Diagnose and Manage CTD-ILD, According to New Research from Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction
From Spherix Global Insights
Via GlobeNewswire
New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments
From Spherix Global Insights
Via GlobeNewswire
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
From Spherix Global Insights
Via GlobeNewswire
Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeline Therapies, According to Spherix Global
From Spherix Global Insights
Via GlobeNewswire
Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Gene Therapy Momentum Builds Among Hematologists in Sickle Cell Disease Management Despite Ongoing Access Barriers, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story